Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Idenix falls on delay for preclinical HCV compound

Idenix Pharmaceuticals Inc. (NASDAQ:IDIX) fell $1.58 (31%) to $3.56 on Friday after reporting the start of

Read the full 169 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE